Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341652 · ClinicalTrials.gov registry record · Phase 2
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT01341652 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 99 participants.
The verdict
NCT01341652, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer. In this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body fight prostate cancer.
Interventions
- BIOLOGICAL pTVG-HP
- BIOLOGICAL rhGM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-05-23 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01341652
The ClinicalTrials.gov registry entry for NCT01341652 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pTVG-HP is the first listed.
NCT01341652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01341652 about?
NCT01341652 is a clinical study titled "Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer". The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer. In this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body...
What is the current status of trial NCT01341652?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2011-05-23. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT01341652?
The interventions under investigation include: pTVG-HP (BIOLOGICAL), rhGM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT01341652?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.